Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Breast Density Clinical Trial

Official title:
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-Response Study of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Status Active, not recruiting

Clinical Trial Summary

This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density. There will be 5 in-clinic visits (Screening, Day 1, Months 1, 3 and 6) and 3 self-report visits (Months 2, 4 and 5). Standard of care mammograms will be used for the screening mammogram as well as the 24-month follow up visit.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Density

Clinical Trial Details

NCT number	NCT05068388
Study type	Interventional
Source	Atossa Therapeutics, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 21, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05900544` - Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures	N/A
Active, not recruiting	`NCT03920098` - Chilean Maternal & Infant Cohort Study II (CHiMINCs-II)
Recruiting	`NCT05181059` - DLSCT for Breast Cancer Detection in Women With Dense Breasts
Completed	`NCT03029286` - ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2	N/A